Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Spotlight: Iraq War Veteran Deploys ‘Bone Paint’ To Combat Traumatic Injuries

Executive Summary

Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.

You may also be interested in...



News We’re Watching: CDRH Announces Cybersecurity Collaboration, Electrostim Faces Lawsuit, FDA Recalls And Approvals

This week, the FDA extended a comment period on digital health tools to detect diabetes; Theradaptive launched a trial of its spinal fusion device; and devices from Hologic and GE Healthcare won FDA clearance.

News We’re Watching – FDA Nixes Neuralink Trials, Layoffs at J&J, Novel Knee Implants

This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials.  Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar. 

Canary Speech’s Voice AI Can Help Detect Alzheimer’s With 40-Second Conversation

AI voice tech start-up Canary Speech is developing algorithmic models for detecting behavioral health, progressive neurological and cognitive diseases based on a 40-second recording of speech. Medtech Insight caught up with Canary CEO Henry O’Connell at DHIS West to learn more about the company and its plans.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel